Preclinical studies of effectiveness and safety of iron oxide nanoparticles based MRI contrast agent for tumor diagnostics.

Abakumov M.A., Prelovskaya A.O., Ternovoy S.K., Demikhov E.I., Majouga A.G., Chekhonin V.P.

Magnetic iron oxide nanoparticles (MNP) show great potential as the contrast agent for magnet-ic resonance imaging (MRI). Purpose. To evaluate the efficiency and safety of the contrast agent based on HSA-coated MNP on the model of the C6 glioma. Materials and methods. Extensive preclinical research of specific activity has been performed. Studies were conducted on the model of the orthotopic C6 glioma. Results. In the preclinical studies, it was demonstrated that HSA-coated magnetic iron oxide nanoparticles (MNP-HSA) accumulate in the tumor and its large vessels. Conclusion. Magnetic resonance imaging with contrast agent allows visualization of the tumor tissue and its vascularization.

1 – Pirogov Russian National Research Medical Universi-ty. 2 – National Research Technological University "MISiS". Biomedical nanomaterials. 3 – Russian Cardiology Research and Production Complex. 4 – I.M. Sechenov First Moscow State Medical Uni-versity (Sechenov University). 5 – P.N. Lebedev Physical Institute of the Russian Academy of Sciences. 6 – Moscow State University. Department of Chemistry. 7 – Dmitry Mendeleev Uni-versity of Chemical Technol-ogy of Russia. Moscow, Russia.

Keywords: magnetic resonance imaging, magnetic nanoparticles, tumor, cancer.

 

Corresponding author: Abakumov M.A., e-mail: Этот e-mail адрес защищен от спам-ботов, для его просмотра у Вас должен быть включен Javascript

For citation: Abakumov M.A., Prelovskaya A.O., Ternovoy S.K., Demikhov E.I., Majouga A.G., Chekhonin V.P. Preclinical studies of effectiveness and safety of iron oxide nanoparticles based MRI contrast agent for tumor diagnostics. REJR 2018; 8 (4):237-241. DOI:10.21569/2222-7415-2018-8-4-237-241.

 

Received:        01.12.18 Accepted:      12.12.18